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ABSTRACT
Background: Effective, evidence-based
management of type 2 diabetes (T2D) requires
the integration of the best available evidence
with clinical experience and patient
preferences.
Methods: Studies published from 2000 to 2012
evaluating glucagon-like peptide-1 receptor
agonists (GLP-1RAs) or dipeptidyl peptidase-4
inhibitors (DPP-4 inhibitors) were identified
using PubMed. The author contextualized the
study findings with his clinical experience.
Results: Incretin-based therapy targets multiple
dysfunctional organs in T2D. Injectable GLP-
1RAs provide substantial glycemic control and
weight reduction; while oral DPP-4 inhibitors
provide moderate glycemic control and weight
neutrality. Both classes are effective, well
tolerated, and associated with a low incidence
of hypoglycemia when used alone or in
combination with other antidiabetes agents.
GLP-1RAs are associated with transient nausea
and, like DPP-4 inhibitors, rare pancreatitis.
Conclusion: Data indicate and clinical
experience confirms that incretins are well
tolerated in appropriate patients and provide
sustained glycemic control and weight loss or
weight neutrality throughout T2D progression.
Keywords: Dipeptidyl peptidase-4 inhibitors;
Endocrinology; Glucagon-like peptide-1
receptor agonists; Glycemic control; Incretin;
Type 2 diabetes; Weight loss
INTRODUCTION
Incretins [glucagon-like peptide 1 (GLP-1) and
glucose-dependent insulinotropic polypeptide
(GIP)] are hormones that stimulate insulin
secretion, inhibit glucagon secretion, delay
gastric emptying, and decrease appetite [1].
They also play an important physiological role
in regulating both first- and second-phase
insulin responses, which are impaired in
patients with type 2 diabetes (T2D) [2].
Recent evidence suggests an approximate 60%
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reduction in the magnitude of incretin effects in
individuals with T2D [2].
Two classes of incretin-based therapies are
currently available: injectable GLP-1 receptor
agonists (GLP-1RAs) and oral dipeptidyl
peptidase-4 inhibitors (DPP-4 inhibitors)
[3–11]. The efficacy, tolerability, and clinical
use of these agents are described in Tables 1, 2,
3, 4, 5, 6, 7, 8, 9 [5–33]. Currently available GLP-
1RAs include liraglutide, exenatide twice daily
(exenatide BID), and exenatide once weekly
[exenatide extended release (EQW)]. Liraglutide
and exenatide BID are administered by pen
devices; EQW is administered as a suspension
with a 23-gage needle and syringe and requires
reconstitution. GLP-1RAs enhance glucose-
dependent insulin secretion by mimicking the
glucoregulatory effects of endogenous GLP-1
and by providing pharmacological (high) levels
of GLP-1 activity, and also suppress glucagon
release (Fig. 1) [1, 34, 35]. In contrast, DPP-4
inhibitors prevent enzymatic inactivation of
endogenous GLP-1, resulting in prolonged
availability of physiological levels of native
GLP-1 and GIP and modest receptor activation
[1]. Sitagliptin, saxagliptin, and linagliptin are
the DPP-4 inhibitors currently available in the
United States. A fourth DPP-4 inhibitor,
alogliptin, has recently been approved. All are
administered orally once daily, with or without
food.
Incretin-based therapies target most of the
dysfunctional organ systems in T2D, potentially
improve b-cell function [18, 22, 36], have
minimal hypoglycemia risk, and are either
weight neutral [31] or induce weight loss [15,
29, 37–43]. However, differences in the
mechanisms of action and pharmacodynamics/
pharmacokinetics, between and within these
classes, can result in important differences in
fasting plasma glucose (FPG), postprandial
glucose (PPG), body weight, b-cell function,
blood pressure (BP), and safety and tolerability
[44], as found in randomized head-to-head
clinical trials (Tables 2, 3, 4, 5, 6, 7, 8, 9 [12–
33]). Numerous reviews have examined the
efficacy and tolerability of GLP-1RAs and DPP-
4 inhibitors based on the results from
randomized controlled trials (RCTs) [34, 45–47],
but few have focused on comparisons among
incretin agents. Moreover, in clinical practice,
the appropriate choice of incretin therapy for a
given patient is not always clear.
Effective evidence-based decision making
requires the integration of clinical experience
with the best available clinical evidence,
provided by data from either RCTs or
systematic research and patient preference [48,
49]. While clinical trials are conducted in highly
selective patient populations with limited
strategies, treatment of T2D in clinical practice
should reflect an individualized, patient-
centered approach that considers the
preferences, needs, and values of individual
patients [3], as indicated by recent treatment
guidelines [3, 4]. This review examines the
clinical evidence surrounding the use of GLP-
1RAs and DPP-4 inhibitors in the context of
more than 25 years in a general endocrinology
practice. Approximately 50–60% of patients
treated in this setting have T2D. It is the
objective of this analysis to help clinicians
both individualize and optimize incretin
therapy in appropriate candidates throughout
the progression of T2D.
METHODS
A PubMed literature search was conducted for
randomized, head-to-head, comparative studies
published between 2000 and 2012 including
GLP-1RAs and DPP-4 inhibitors. In addition,
randomized, controlled studies for
monotherapy and combination therapy
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published between 2000 and 2012 and internal
references on incretins and incretin-based
therapies were considered. Specific search
terms included glucagon-like peptide-1, GLP-
1RAs, exenatide, liraglutide, dipeptidyl
peptidase 4, DPP-4 inhibitors, sitagliptin,
saxagliptin, and linagliptin.
Compliance with Ethics Guidelines
The analysis in this article is based on
previously conducted studies and does not
involve any new studies of human or animal
subjects performed by the author.
ROLE OF INCRETIN THERAPIES
IN DIABETES MANAGEMENT
Guidelines currently include incretin therapies
at all stages of pharmacologically treated T2D
[3, 4]. They are recommended for initial therapy
(usually in combination with metformin and
also as monotherapy in some patients), as add-
on therapy to oral agents, and even in
combination with insulin with or without
additional therapies [3, 4, 50].
NEWLY DIAGNOSED, TREATMENT-
NAIVE PATIENTS
Recommendations for the initial use of
metformin in newly diagnosed patients are
nearly universal, unless it is contraindicated.
However, some patients with high hemoglobin
A1c (A1C) at diagnosis are unlikely to achieve
their individualized glycemic goals on
metformin alone and may require initial
combination therapy, which should include
classes of medications with complementary
modes of action [4] to effectively target the
underlying multiorgan pathophysiology of
T2D. Balancing adverse events (AEs) and
treatment benefits, particularly the risk for
hypoglycemia, is also important. One
important option for initial combination
therapy is metformin with a GLP-1RA or a
DPP-4 inhibitor.
Data on initial combination therapy with
GLP-1RAs and metformin in treatment-naive
patients inadequately controlled on diet and
exercise alone are limited, and no studies have
compared initial combination therapy with
metformin and GLP-1RAs or DPP-4 inhibitors.
However, initial combination therapy with
metformin and sitagliptin, saxagliptin, or
linagliptin has been evaluated in several
clinical trials [51–53]. In these trials, mean
A1C reductions with initial combination
therapy with a DPP-4 inhibitor and metformin
2,000 mg/day ranged from 1.7 to 2.5%. DPP-4
inhibitors were generally well tolerated in these
trials. Rates of hypoglycemia were low and AEs
occurred at a similar frequency across groups in
each study.
GLP-1RAs and metformin as initial therapy
have not been extensively evaluated, but GLP-
1RAs have been studied as add-on therapy to
metformin in numerous trials. Results from
these trials may provide some insight as to the
potential effects of this combination as initial
therapy. Such trials have demonstrated
reductions in A1C of 0.8–1.5%, with weight
loss of 2.3–2.8 kg [19, 54, 55]. Comparative data
on the relative impact of incretin therapies
among patients inadequately controlled on
metformin will be considered later in the
manuscript.
Clinical Experience with Incretins
as Initial Therapy
In newly diagnosed patients requiring more
than metformin to get to their individualized
306 Adv Ther (2014) 31:289–317
A1C goal, the choice for incretin therapy
depends on several factors, including baseline
A1C, body mass index, and comorbidities. GLP-
1RA plus metformin for obese patients with
high A1C typically works well. It is possible to
achieve glycemic targets in patients at A1C 10%
with GLP-1RAs and metformin [22]. In
addition, the sustained weight loss associated
with GLP-1RAs in clinical trials—which can be
impressive in some patients—is beneficial to
many organ systems [26]. Because of the limited
glucose-lowering potential of DPP-4 inhibitors,
metformin with a DPP-4 inhibitor in patients
with baseline A1C C10% will not get most
patients to their goal. Although there is
evidence suggesting that DPP-4 inhibitors are
less effective in patients with A1C \8% [56],
DPP-4 inhibitors can be used in patients with
lower A1C when they are of normal weight,
particularly when they resist injections.
For patients with high A1C, symptoms of
hyperglycemia, and significant glucotoxicity,
the use of insulin is recommended in current
treatment guidelines. In the author’s clinical
experience, patients can be weaned off insulin,
as glucotoxicity abates, and initiated on
metformin and a GLP-1RA. While clinical data
on this approach are limited, it has been
successful in the author’s practice.
INCRETIN AGENTS
AS MONOTHERAPY
There are some newly diagnosed patients in
whom metformin is inappropriate or
contraindicated. Incretin-based therapies may
be a useful option in this population, which
includes patients with moderate-to-severe renal
impairment or heart failure.
However, patients with severe renal
impairment or end-stage renal disease (ESRD)
may also be poor candidates for some incretin
therapies. Because they are cleared through the
kidney, exenatide BID and EQW should not be
used in this population [5, 7]. Although
liraglutide is not cleared by renal mechanisms
and no differences in safety and efficacy were
found in patients with mild renal impairment
in a meta-analysis of the Liraglutide Effect and
Action in Diabetes (LEAD) clinical trial program
[57], caution and careful monitoring should still
be used when initiating liraglutide in such
patients [7]. Sitagliptin, saxagliptin, and
alogliptin, but not linagliptin, require dose
Fig. 1 Mechanism of Action of GLP-1RAs and DPP-4
inhibitors. DPP-4 inhibitors dipeptidyl peptidase-4
inhibitors, GIP glucose-dependent insulinotropic
polypeptide, GLP-1 glucagon-like peptide-1. Reprinted
with permission from McDougall et al [35]. Drugs for
diabetes: part 5. DPP-4 inhibitors
Adv Ther (2014) 31:289–317 307
reductions in patients with renal impairment or
ESRD [8–11].
Although data from head-to-head studies of
incretin therapies in drug-naive patients with
T2D are relatively rare, and no studies have
directly compared different DPP-4 inhibitors,
the limited comparisons between GLP1-RAs and
DPP-4 inhibitors and between various GLP-1RAs
can help guide the physician in their choice of
incretin therapy, if metformin is not an option.
Data from RCTs comparing EQW with
sitagliptin monotherapy showed significantly
greater reductions in FPG, A1C, and body
weight, and showed that a significantly higher
proportion of patients achieved a target A1C
level of\7.0% or B6.5%, with EQW. Moreover,
there were no significant differences between
EQW and metformin monotherapy on
reductions in FPG or A1C or on the
proportion of patients achieving a target A1C
level of \7.0% [21], suggesting similar
outcomes.
Among patients who managed their diabetes
with diet and exercise alone, EQW provided
significantly greater reduction in A1C, FPG, and
weight compared with exenatide BID. A
significantly higher proportion of patients
achieved target A1C levels of \7.0% and
B6.5% with EQW [27]. Few head-to-head data
on the use of liraglutide compared with other
incretin agents in treatment-naive patients are
available. However, patients treated with
liraglutide monotherapy showed significantly
greater reductions in A1C from baseline,
compared with glimepiride [58, 59].
Clinical Experience with Incretins
in Monotherapy
Although prescribing information for
liraglutide or EQW advises against using these
agents as first-line therapy, they are typically
my preferred alternative to metformin if
metformin cannot be used. GLP-1RAs may be
particularly suitable because they are effective,
may facilitate weight loss, and are associated
with a low risk of hypoglycemia. When
considering GLP-1RAs, the author’s patients
usually receive the longer-acting GLP-1RAs,
liraglutide and EQW, instead of exenatide
BID, because they are dosed less frequently
and have a superior effect on fasting glucose
[22, 27].
In patients with moderate-to-severe renal
impairment who require A1C reductions [1%
or who would benefit from weight loss,
liraglutide is preferred because exenatide BID
and EQW should not be used in such patients,
but it should be used with caution [5–7].
Linagliptin or reduced-dose sitagliptin or
saxagliptin is each a useful option in nonobese
patients and/or if a patient with renal
insufficiency requires B1% A1C reduction [60].
DPP-4 inhibitors may be particularly
appropriate as initial therapy in frail or slim
elderly patients with renal impairment,
moderately elevated A1C, and elevated PPG
without a substantially elevated FPG [60].
Incretins, including GLP-1RAs, are also
useful in patients who cannot tolerate the
gastrointestinal (GI) side effects of metformin.
In the author’s experience, GI symptoms with
GLP-1RAs are self-limiting and disappear over
time, unlike the GI symptoms often observed
with metformin. In elderly patients with severe
anorexia with metformin monotherapy,
monotherapy with a DPP-4 inhibitor is an
important option.
Sulfonylureas may also be an option for
patients who refuse incretin therapy, but their
potential adverse effects on b-cells [61], elevated
risk of hypoglycemia, tendency toward weight
gain [3, 4], and limited effectiveness over time
should be considered carefully [62]. Compared
308 Adv Ther (2014) 31:289–317
with sulfonylureas, monotherapy studies with
incretin-based therapies demonstrate better
safety, and in the case of GLP-1RAs, better
efficacy [63, 64].
Similarly, the author tends to choose
incretins over thiazolidinediones (TZDs) in
many patients because of the potential adverse
effects of TZDs, including weight gain,
peripheral edema, and increased risk of
congestive heart failure [3].
INCRETINS AS ADD-ON THERAPY
Use of incretins in dual therapy may be
considered after lifestyle and drug
monotherapy become insufficient and before
b-cell function ceases and insulin therapy
becomes the only option.
Incretin Plus Metformin Therapy
In head-to-head studies comparing GLP1-RAs
with DPP-4 inhibitors, incretin-based therapies
have demonstrated modest to robust effects on
glycemic indices in patients on metformin, with
greater reductions in FPG and A1C with GLP1-
RAs, compared with DPP-4 inhibitors. For
example, in a head-to-head comparison of
EQW with sitagliptin, in which each was used
as add-on therapy to metformin, A1C reduction
was significantly greater with EQW, overall, as
well as among patients with A1C levels C9%
[19]. Similarly, in a head-to-head comparison of
liraglutide and sitagliptin in patients with
inadequate control on metformin, liraglutide
was associated with significantly greater
reductions in A1C, FPG, and body weight with
a similar incidence of hypoglycemia [12, 13].
In both trials, nausea and vomiting were
more common with GLP-1RAs than sitagliptin
[12, 13, 19].
Two studies have also compared the efficacy
of liraglutide to exenatide BID [22] and EQW
[24] in patients inadequately controlled on
metformin, sulfonylurea, or both (in the
exenatide BID trial) or metformin,
sulfonylurea, and/or pioglitazone (in the EQW
trial). In the first trial, liraglutide provided
significantly greater improvements in A1C
(1.1% vs 0.8%, P\0.0001) than EQW [22].
While both agents were well tolerated, nausea
was less persistent and hypoglycemia less
frequent with liraglutide than with exenatide
BID. When compared with EQW, liraglutide was
associated with greater reductions in A1C
(1.48% vs 1.28%) and body weight (3.6 vs
2.7 kg); however, EQW was associated with
less nausea and vomiting [24]. Reductions in
systolic BP (SBP) were also similar between
groups.
Blood pressure management is an
important component of treatment in all
patients with T2D [65]. Liraglutide, exenatide
BID, EQW, and sitagliptin generally show
similar reductions in SBP, while diastolic BP
is not affected [12–14, 22, 24, 25]. One study
of EQW showed greater reduction in SBP
compared with sitagliptin [19]. While BP
reductions are generally beneficial and
cardiovascular risk reduction is a priority in
diabetes management, the author uses incretin
therapies in their practice for their glycemic
and weight effects and not their impact on
BP.
Clinical Experience with Incretins
as Add-on Therapy to Metformin
The use of incretin therapy as add-on therapy
with metformin is recommended in treatment
guidelines and it is the author’s primary
intervention in most patients on metformin
whose A1C is above their target goal [3, 4]. The
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greater A1C reduction and weight loss
associated with GLP-1RAs make them my
preferred incretin therapy in most patients.
Most of the author’s patients lose
approximately 3–4.5 kg on GLP-1RAs, but
some may experience more dramatic weight
reductions of up to 13–18 kg.
In fact, the need for weight loss may drive
the choice of GLP1-RAs over DPP-4 inhibitors in
some patients, and may persuade patients to
choose injections over oral therapy. Moreover,
DPP-4 inhibitors are postprandial modulators
that may be less useful than longer-acting
GLP1-RAs in patients with FPG [200 mg/dL.
When the injection barrier is insurmountable,
DPP-4 inhibitors can be prescribed; however,
patients should be actively involved in the
decision-making process. In nonobese patients
requiring \1% reduction in A1C, a DPP-4
inhibitor can be used if the patient prefers.
However, the author usually switches patients
already on DPP-4 inhibitors to GLP-1RAs if they
require an additional 0.5% A1C reduction.
Head-to-head clinical trials demonstrate that
the more protracted agents have fewer GI
symptoms, with exenatide BID causing the
most GI symptoms, followed by liraglutide,
and then EQW [22, 24, 25]. In the author’s
experience, many patients who did not tolerate
exenatide BID are able to successfully use
liraglutide and EQW.
Before initiating any GLP-1RA, patients
should be informed of the potential for GI
AEs. To mitigate symptoms with exenatide and
liraglutide, treatment should be initiated at a
lower dose and titrated up to achieve maximal
effect. For example, if patients experience
nausea with liraglutide, the dose is increased
only when the nausea is resolved. In the rare
event that nausea remains an issue, the titration
of the liraglutide dose can be slowed. This
technique has been found to be effective, even
though it is not specifically recommended in
the labeling [7]. EQW is not usually titrated, but
the author’s patients with nausea on exenatide
BID do not use the 10-mcg dose until the nausea
abates.
Incretin Plus Sulfonylurea Therapy
Both sulfonylureas and incretins stimulate
release of insulin from pancreatic b-cells [34,
66]. Insulin release by sulfonylureas is glucose
independent (primarily affects FPG) and
increases the risk for hypoglycemia.
Conversely, incretins stimulate insulin in a
glucose-dependent manner, minimizing risk of
hypoglycemia. Therefore, combining incretin
therapy with a sulfonylurea potentially allows
for lowering of the sulfonylurea dose and a
possible reduction in the risk of hypoglycemia,
while maintaining or increasing glycemic
control [5–7, 67]. While results from clinical
trials indicate that adding an incretin to a
sulfonylurea reduces A1C by 0.5–1.1% [64, 67,
68], there are few data on the comparative
impact of incretin agents in patients
inadequately controlled on sulfonylureas alone.
In patients already using sulfonylureas who
need an A1C reduction of 1–1.5%, the dose of
sulfonylurea should be reduced when DPP-4
inhibitors or GLP-1RAs are added. However, the
current sulfonylurea dose should be maintained
if an A1C reduction of [1.5% is needed. The
author also asks patients receiving sulfonylurea
therapy in combination with an incretin for an
extra fingerstick glucose measurement before
dinner.
USE OF INCRETINS IN TRIPLE
THERAPY
While guidelines often recommend insulin
therapy as the preferred option for patients
310 Adv Ther (2014) 31:289–317
inadequately controlled on metformin and an
additional agent, many patients receive triple
therapy at this stage, particularly if they are
reluctant to initiate insulin.
Incretin Plus Metformin and Sulfonylurea
Although several studies have evaluated the use
of incretin therapy in combination with
metformin and a sulfonylurea, there have been
no such head-to-head comparisons. In one
study, liraglutide added to metformin and a
sulfonylurea reduced A1C by 1.3% and
decreased weight by 1.8 kg [69]. A similar study
of exenatide BID reported a reduction in A1C of
1.0% and a weight loss of 2.5% [70]. In these
trials, hypoglycemia was reported by 27% [69] of
patients on liraglutide and 27% of patients on
exenatide [70]. In a study evaluating sitagliptin
in combination with metformin and a
sulfonylurea, the combination reduced A1C by
0.9% but increased weight by 0.8 kg [71]. The
incidence of hypoglycemia with the sitagliptin
combination was 16.4%.
The combination of metformin,
sulfonylurea, and a GLP-1RA is the author’s
preferred noninsulin-based triple therapy,
because this combination is effective in
reducing A1C and FPG with few hypoglycemic
events. To avoid hypoglycemia when using this
combination, the sulfonylurea dose typically
should be reduced when adding an incretin
therapy.
Incretin Plus Metformin and TZD Therapy
Adding GLP-1RA to TZD therapy for patients
inadequately controlled with TZD and
metformin leads to complementary effects: an
increase in b-cell insulin secretory function
(GLP-1RAs), inhibition of glucose production
by the liver (metformin), and an increase in
glucose uptake by muscle (TZD), and
consequently, improved glycemic control [72].
Combining incretins with TZDs may also
mitigate the adverse effect of TZDs on weight.
Data on the comparative use of incretin
therapies with TZDs and metformin are
limited. However, a study of liraglutide with
metformin and a TZD reported a reduction in
A1C of 1.5% with a reduction in weight of
1–2 kg and an incidence of hypoglycemia of
7.9–9.0% [73].
INCRETIN PLUS INSULIN THERAPY
In many patients, addition of insulin to oral
antidiabetic drugs (OADs) or GLP-1RAs is
required to meet treatment goals. New studies
demonstrate the utility of combining basal
insulin with incretin therapies. When used in
combination with GLP-1RAs or DPP-4
inhibitors, exogenous insulin is augmented
with endogenous, glucose-dependent insulin
secretion, allowing the body to compensate for
increased carbohydrate intake without
increasing the dose of exogenous insulin and,
consequently, risk of hypoglycemia [28,
31–33]. Complementary combination therapy
can be accomplished by adding a short-acting
incretin agent (exenatide) that primarily targets
PPG to basal insulin that primarily targets FPG
[29].
Longer-acting liraglutide in combination
with basal insulin has also shown to improve
glycemic indices. Liraglutide targets both FPG
and PPG, without the increase in hypoglycemia
or weight gain associated with increased insulin
dosing. Addition of GLP-1RAs allows for
lowering the basal insulin dose and may even
eliminate the need for prandial insulin [15, 29].
In fact, insulin doses should be reduced when
initiating GLP-1RAs in patients on insulin. With
DPP-4 inhibitors, the basal insulin dose stays
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the same since FPG changes are minimal
[31–33]. Incretin therapies are useful in
patients taking insulin, even if only to prevent
the intensification of basal insulin regimens to
multiple daily injections.
LONG-TERM SAFETY OF INCRETIN
THERAPIES
Pancreatitis
Pancreatitis has been reported in post-
marketing surveillance for both GLP-1RAs
and DPP-4 inhibitors [74]. In patients with
risk factors for pancreatitis, including
gallstones, high triglycerides, or excessive
alcohol intake, incretins should be used with
caution. Liraglutide, exenatide BID, and EQW
are not recommended in patients with a
history of pancreatitis [5–7]. Before initiating
incretin therapy, the possible risk for
pancreatitis with patients should be
discussed. Patients should be advised to
contact their health care provider
immediately if they experience severe
abdominal pain. While careful observation
for signs and symptoms of pancreatitis is
recommended following incretin initiation,
the totality of clinical, preclinical, and post-
marketing evidence does not clearly
substantiate an association between incretin
therapies and acute pancreatitis, although
published opinions on this topic differ
[75–77]. The author has had no experience
with pancreatitis in patients using incretin
therapy. Moreover, experts convened by the
National Institute of Diabetes and Digestive and
Kidney Diseases in June 2013 concluded that
there is likely no increased risk for pancreatic
cancer associated with incretin therapies,
although longer-term studies are needed [78].
Thyroid Neoplasm
Based on preclinical data, liraglutide and
exenatide BID are absolutely contraindicated
in patients with a personal or family history of
medullary thyroid carcinoma and in patients
with multiple endocrine neoplasia syndrome
type 2 [6, 7]. Although rare (the author has seen
medullary thyroid carcinoma three times in
25 years), the author recommends palpating the
patient’s thyroid gland to examine for nodules
before starting therapy.
CONCLUSION
Incretins play an important role in normal
glucose homeostasis, and incretin therapies
should be considered in combination
treatment regimens for patients with T2D
from early onset to late disease. The selection
of a particular agent should be individualized
and depends on patient characteristics,
preferences, and treatment goals, as well as
differences in overall clinical profiles among
incretin agents.
In clinical trials and in my own clinical
experience, GLP-1RAs have shown greater and
sustained glycemic control compared with DPP-
4 inhibitors, with the additional benefits of
weight loss and reduced SBP. High patient
satisfaction has been reported with GLP-1RAs
despite the subcutaneous route of
administration [38, 79–81]. In combination
therapy with insulin, GLP-1RAs lead to
sustained glycemic control, along with
reduced insulin doses without increase in
hypoglycemia or weight gain.
As a whole, the incretin class of antidiabetes
agents is very useful, and both DPP-4 inhibitors
and GLP-1RAs have improved T2D
management. Many patients now consider
312 Adv Ther (2014) 31:289–317
injectable therapy in view of the observed
benefits of GLP-1RAs and those who
succeed with this therapy are satisfied with the
results.
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